CD274 and glioblastoma: Two trials are addressing the efficacy of other ICB, the anti-PD-L1 antibody durvalumab (human IgG1) in patients with newly diagnosed or recurrent GBM (NCT02336165) and an anti-LAG3 antibody compared to an anti-CD137 (urelumab, a fully human IgG4 antibody) combined or not with pembrolizumab (NCT02658981).